FDA’s Greatest Biosimilar Impact May Be Interchangeability Policy, Sandoz Says
This article was originally published in The Pink Sheet Daily
Executive Summary
As the agency and stakeholders gear up for public hearing, Sandoz argues that since Europe has not addressed interchangeability, FDA could step to the forefront by focusing on it as part of implementing the U.S. biosimilar pathway.
You may also be interested in...
Sandoz Pushing FDA To Make Biosimilar Interchangeability Decisions
Absent guidance, the company says it is submitting proposals for trial designs it believes could demonstrate biosimilar interchangeability.
Biosimilars’ Next Big Hurdle For FDA Could Be Clinician Education
Companies and other groups want clear FDA communication on biosimilars as pharmacists look for an Orange Book-like reference manual to be ready for prescriptions.
Biosimilar Suffix Naming Idea Trips On Dispensing Problem
American Pharmacists Association tells FDA during biosimilar guidance hearing that using suffixes to create unique names will be problematic. FDA may be leaning toward the unique names, saying published literature indicates adequate safety tracking is not possible without them.